Aratana Therapeutics, Inc. (NASDAQ:PETX) Weekly Ratings as of Apr 17, 2018

April 17, 2018 - By Sheila Anderson

Aratana Therapeutics, Inc. (NASDAQ:PETX) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.56. That’s change of 0.16, from 2017Q3’s 1.72. 13 investors sold all, 19 reduced holdings as Aratana Therapeutics, Inc. ratio turned negative. 29 grew stakes while 21 funds took stakes. Funds hold 30.34 million shares thus 3.78% less from 2017Q3’s 31.53 million shares.
Mpm Asset Mgmt Ltd Liability Co holds 0.53% of its capital in Aratana Therapeutics, Inc. (NASDAQ:PETX) for 250,000 shs. Manufacturers Life Insur Company The holds 0% of its capital in Aratana Therapeutics, Inc. (NASDAQ:PETX) for 35,139 shs. General Amer Investors Com holds 0.57% in Aratana Therapeutics, Inc. (NASDAQ:PETX) or 1.12 million shs. Gru One Trading L P owns 6,219 shs or 0% of their US capital. Davenport Limited Liability reported 177,000 shs or 0.01% of all its holdings. Renaissance Technology Limited Liability Com has 124,800 shs for 0% of their capital. Broadfin Cap Limited Co has 3.69% invested in Aratana Therapeutics, Inc. (NASDAQ:PETX). Jacobs Levy Equity Management holds 0.01% or 67,800 shs in its capital. Cubist Systematic Strategies Ltd Liability Company has invested 0% in Aratana Therapeutics, Inc. (NASDAQ:PETX). Adams Asset Ltd Co has invested 0.01% in Aratana Therapeutics, Inc. (NASDAQ:PETX). Aqr Mngmt Lc reported 24,421 shs stake. Bancorp Of New York Mellon Corp holds 0% or 144,558 shs. Ubs Asset Mngmt Americas invested in 1,629 shs or 0% of the stock. Advisory Serv Network Ltd Limited Liability Company stated it has 7,000 shs or 0% of all its holdings. Tiaa Cref Inv Management Ltd Company reported 104,420 shs.

Aratana Therapeutics, Inc. had 2 selling transactions and 0 buys since January 11, 2018. This’s net activity of $250,341. On Thursday, January 11 TOOMAN CRAIG A also sold $158,040 worth of Aratana Therapeutics, Inc. (NASDAQ:PETX).

Aratana Therapeutics, Inc. (NASDAQ:PETX) Ratings Coverage

In total 5 analysts cover Aratana (NASDAQ:PETX). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 11 are the (NASDAQ:PETX)’s analyst reports since October 23, 2017 according to StockzIntelligence Inc. On Tuesday, March 27 the company was upgraded by Stifel Nicolaus. On Monday, March 12 the firm has “Buy” rating given by C.L. King. In Wednesday, December 27 report C.L. King initiated the stock with “Hold” rating. On Friday, March 16 Credit Suisse maintained Aratana Therapeutics, Inc. (NASDAQ:PETX) with “Outperform” rating. On Friday, November 3 the firm has “Buy” rating given by Jefferies. On Monday, December 18 the firm has “Hold” rating by Stifel Nicolaus given. On Wednesday, November 15 the firm has “Buy” rating given by Jefferies. The stock rating was maintained by Stifel Nicolaus with “Hold” on Monday, October 23. On Monday, March 19 the firm has “Buy” rating by H.C. Wainwright given. On Tuesday, January 16 the stock of Aratana Therapeutics, Inc. (NASDAQ:PETX) earned “Buy” rating by H.C. Wainwright. Listed here are Aratana Therapeutics, Inc. (NASDAQ:PETX) PTs and latest ratings.

27/03/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Buy Upgrade
19/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
16/03/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $9 New Target: $8 Maintain
12/03/2018 Broker: C.L. King Rating: Buy New Target: $7.5 Upgrade
16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
27/12/2017 Broker: C.L. King Rating: Hold Initiate
18/12/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $6.0 Maintain
15/11/2017 Broker: Jefferies Rating: Buy New Target: $8.5 Maintain
17/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10 Initiates Coverage On
03/11/2017 Broker: Jefferies Rating: Buy New Target: $8.0 Maintain

On during the last trading session the stock increased $0.08 or 1.56%, reaching $5.22.Aratana Therapeutics, Inc. has volume of 68,297 shares. Since April 17, 2017 PETX has declined 14.71% and is downtrending. The stock underperformed the S&P 500 by 26.26%.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium.The firm is worth $239.36 million. The Company’s product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.Last it reported negative earnings. The firm markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs.

Aratana Therapeutics, Inc. (NASDAQ:PETX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: